GLP-1 receptor agonists like semaglutide and tirzepatide produce region-specific facial volume loss following predictable anatomical patterns, prompting plastic surgeons to develop a risk stratification model based on individual facial phenotypes. The proposed four-phase prevention algorithm aligns interventions with weight-loss kinetics rather than waiting for damage to occur. This represents a notable shift in aesthetic medicine thinking—moving from reactive cosmetic correction toward preventive intervention based on biological mechanisms. The facial volume changes appear linked to the drugs' effects on subcutaneous fat distribution, particularly in areas with thinner tissue planes. However, this remains a conceptual framework without clinical validation data. The practical implications are significant given that over 15 million Americans now use GLP-1 medications, many unaware of potential facial aging acceleration. The authors acknowledge this is hypothesis-generating Level V evidence, meaning it's expert opinion rather than controlled research. While the preventive approach is logical, patients and providers need robust clinical trials to determine if early interventions actually prevent the 'Ozempic face' phenomenon or simply delay inevitable changes.